Health
Ortho’s VITROS® SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Performance, Sensitivity Data – PRNewswire
/PRNewswire/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it received…
RARITAN, N.J., March 23, 2021 /PRNewswire/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it received authorization from the U.S. Food and Drug Administration to update key claims for the VITROS® SARS-CoV-2 Antigen Test, the first high-volume SARS-CoV-2 antigen assay to receive Emergency Use Authorization (EUA) in the United States.
“Communities and laboratories across the United States continue to seek fast, reliable,…
-
General22 hours agoMatildas vs Panama international friendly — live blog and scores from Bunbury
-
General22 hours agoTariff letters to 12 countries going out Monday: Trump
-
Noosa News23 hours agoPolice appeal for information after two men found dead
-
General23 hours agoCan the world be governed without the US? • Inside Story